ArticleAntimicrobial agents and chemotherapy2008
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Potential protective effect of 3,3'-methylenebis(1-ethyl-4-hydroxyquinolin-2(1H)-one) against bleomycin-induced lung injury in male albino rat via modulation of Nrf2 pathway: biochemical, histological, and immunohistochemical study.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Design, Synthesis, Molecular Docking, Antiapoptotic and Caspase-3 Inhibition of New 1,2,3-Triazole/Molecules (Basel, Switzerland) · 2020Article
- Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication.Scientific reports · 2016Article
- Benzotriazole: An overview on its versatile biological behavior.European journal of medicinal chemistry · 2015Review
- Substrate recognition by norovirus polymerase: microsecond molecular dynamics study.Journal of computer-aided molecular design · 2013Article
- Hepatitis C virus NS3 inhibitors: current and future perspectives.BioMed research international · 2013Review
- Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.Journal of medicinal chemistry · 2012Article
- Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.The Journal of antimicrobial chemotherapy · 2011Article
- Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.Antimicrobial agents and chemotherapy · 2011Article
- Inhibition of RNA Helicases of ssRNA(+) Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families.International journal of medicinal chemistry · 2011Review
- A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities.Methods in molecular biology (Clifton, N.J.) · 2010Article
- Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.Future virology · 2009Article
- In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report here a comparative study of the anti-hepatitis C virus (HCV) activities of selected (i) nucleoside polymerase, (ii) nonnucleoside polymerase, (iii) alpha,gamma-diketo acid polymerase, (iv) NS3 protease, and (v) helicase inhibitors, as well as (vi) cyclophilin binding molecules and (vii) alpha 2b interferon in four different HCV genotype 1b replicon systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.